Shareprice
01 Dec 2023

Pipeline

Our pipeline holds proprietary clinical-stage assets and projects in the preclinical and research phases, all aimed at developing and commercializing applications arising from our unique technology platform.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Pipeline

FluoGuide’s pipeline is under continuous development, yet focused on aggressive brain cancer and lung cancer. However, FluoGuide technology is widely applicable across multiple cancer types.

Pre-clinical
Phase I
Phase II
Phase III
Commercial
FG001
Aggressive Brain cancer
Info
Next milestone: Consolidated plans
Head and Neck cancer
Info
Next milestone: Consolidated plans
Lung cancer
Info
Next milestone: Consolidated plans
Follow-on pipeline
FG002
Info
Next milestone: CTA submission
Photothermal therapy
Info
Next milestone: Plans and timelines
Completed
Ongoing